Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and {REMOVEPT} price target on aTyr Pharma (NASDAQ: ATYR).

The analyst commented, “We Are Hosting aTyr Management for a Virtual Fireside Chat. aTyr has a big P3 binary in 3Q25 for efzofitimod in pulmonary sarcoidosis. We will go through the key investor debates around this readout in detail. We will touch on the expectations for the interim P2 readout in 2Q25 for efzofitimod in SSc-ILD.”

For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.

Shares of aTyr Pharma closed at $3.10 yesterday.

You May Also Be Interested In

• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
• UBS Reiterates Neutral Rating on Gentex (GNTX) Ahead of Investor Day
• DA Davidson Reiterates Buy Rating on Standex International (SXI)